4.8500 -0.02 (-0.41%)
After hours: 5:27PM EDT
|Bid||4.8600 x 39400|
|Ask||4.8700 x 4000|
|Day's Range||4.8200 - 5.2500|
|52 Week Range||4.8200 - 34.6300|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.40|
BOULDER, Colo.-- -- Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in ovarian cancer based on response to prior platinum-based chemotherapy Integrated safety analysis of Rubraca in ovarian cancer treatment and maintenance treatment settings Clovis Oncology, ...
Clovis Oncology, Inc. today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM Eastern Time.
Clovis Oncology, Inc. (CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 4.50% Convertible Senior Notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to exercise their option to purchase an additional $13.0 million aggregate principal amount of the notes. Clovis Oncology intends to use the net proceeds from the exercise of this option for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib), funding of Clovis Oncology’s development programs, payment of milestones pursuant to Clovis Oncology’s license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses, repurchase or repayment of other debt obligations and working capital.
President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share. Continue reading...
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.
Clovis Oncology, Inc. (CLVS) announced today the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology has also granted to the initial purchasers a 13-day option to purchase up to $37.5 million aggregate principal amount of additional notes on the same terms and conditions. The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date at an initial conversion rate of 137.2213 shares of Clovis Oncology’s common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $7.29 per share of common stock.
Clovis Oncology, Inc. (CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology also expects to grant the initial purchasers a 13-day option to purchase up to $33.75 million aggregate principal amount of additional notes on the same terms and conditions. Clovis Oncology will not have the right to redeem the notes prior to their maturity.
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
Anyone researching Clovis Oncology, Inc. (NASDAQ:CLVS) might want to consider the historical volatility of the share...
Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.40 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]